Top Line: ERSPC, the trial everyone loves to hate.
The Study: The European Randomized Study of Screening for Prostate Cancer (ERSPC) began in 1993 to determine if population-based PSA testing reduces prostate cancer mortality. Across eight countries, 162,000 men aged 55–69 were randomized to PSA screening every 2–4 years versus usual care. We now have an updated analysis after a median follow-up of 23 years reporting prostate cancer mortality was 13% lower in the screened group (RR 0.87), corresponding to an absolute risk reduction of 0.22%. That’s 1 prostate cancer death prevented per 456 men screened—a notable improvement from 1 in 628 at 16 years. Looked at another way, 1 prostate cancer death was prevented per 12 prostate cancer diagnoses—up from 1 per 18 diagnoses at 16 years. While concerns of overdiagnosis of clinically-insignificant cancers remain founded, the risk/benefit of PSA screening is proving to lean towards benefit more with each passing year, not least because the ramifications of undiagnosed prostate cancer may well take two decades to manifest. And all of this is absent ever-more sophisticated screening algorithms in play in 2025 and beyond to successfully slash therapies for, and even biopsies of, clinically-insignificant prostate cancer.
TBL: Long-term data confirm PSA screening modestly but durably reduces prostate cancer mortality, with diminishing downsides with evolving screening algorithms. | Roobol, N Engl J Med 2025
The Study: The European Randomized Study of Screening for Prostate Cancer (ERSPC) began in 1993 to determine if population-based PSA testing reduces prostate cancer mortality. Across eight countries, 162,000 men aged 55–69 were randomized to PSA screening every 2–4 years versus usual care. We now have an updated analysis after a median follow-up of 23 years reporting prostate cancer mortality was 13% lower in the screened group (RR 0.87), corresponding to an absolute risk reduction of 0.22%. That’s 1 prostate cancer death prevented per 456 men screened—a notable improvement from 1 in 628 at 16 years. Looked at another way, 1 prostate cancer death was prevented per 12 prostate cancer diagnoses—up from 1 per 18 diagnoses at 16 years. While concerns of overdiagnosis of clinically-insignificant cancers remain founded, the risk/benefit of PSA screening is proving to lean towards benefit more with each passing year, not least because the ramifications of undiagnosed prostate cancer may well take two decades to manifest. And all of this is absent ever-more sophisticated screening algorithms in play in 2025 and beyond to successfully slash therapies for, and even biopsies of, clinically-insignificant prostate cancer.
TBL: Long-term data confirm PSA screening modestly but durably reduces prostate cancer mortality, with diminishing downsides with evolving screening algorithms. | Roobol, N Engl J Med 2025

